ROS1
Proto-oncogene tyrosine-protein kinase ROS
As of the edition of 20 October 2026, ROS1 (proto-oncogene tyrosine-protein kinase ROS, UniProt P08922) has 8 drugs tested at it and 11 companies on the list, 0 on route A and 6 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P08922
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 5
- Disease areas
- Cancer; Lungs and airways; Blood and lymph; Immune system; Digestive system; Skin and connective tissue; Urinary and reproductive; Hormones
- Registered trials of its drugs
- 182
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 5 |
| Active | 2 |
| Status not established | 1 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Crizotinib | Marketed | Phase 4 | Ends 2029 |
| Entrectinib | Marketed | Phase 4 | Ends 2037 |
| Repotrectinib | Marketed | Phase 3 | Ends 2036 |
| Taletrectinib | Marketed | Phase 3 | Ends 2033 |
| Iruplinalkib | Active | Phase 2 | none listed |
| APG-2449 | Active | Phase 1 | none listed |
| Zidesamtinib | Marketed | Phase 2 | Ends 2042 |
| SAF-189s | Status not established | Phase 2 | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 6 |
| Engaged | 4 |
| Undetermined | 1 |
| Total on the list | 11 |
| Company | Route |
|---|---|
| Pfizer | Route B |
| Nuvation Bio | Route B |
| Roche | Route B |
The other 8 companies at ROS1
In the product11 companies in all; 8 are not named here, and no score is.
See the 11 companies at ROS1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.